Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice

Oncogene

Volumn 21, Issue 52, 2002, Pages 7945-7956

  Hawighorst, Thomas ^a   Oura, Hajimu ^a   Streit, Michael ^a   Janes, Lauren ^a   Nguyen, Lynh ^a   Brown, Lawrence F ^b   Oliver, Guillermo ^c   Jackson, David G ^d   Detmar, Michael ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Chemoprevention; LYVE 1; Prox1; TSP 1; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; CD36 ANTIGEN; THROMBOSPONDIN 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; EPIDERMIS; EPITHELIUM HYPERPLASIA; GENE OVEREXPRESSION; LYMPH NODE METASTASIS; LYMPH VESSEL; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TRANSGENIC MOUSE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; LYMPHATIC METASTASIS; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS; THROMBOSPONDIN 1;

ANIMALIA; MUS MUSCULUS;

EID: 0037079243     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1205956     Document Type: Article

References (42)

1. Alvarez AA, Axelrod JR, Whitaker RS, Isner PD, Bentley RC, Dodge RK and Rodriguez GC. (2001). Gynecol., Oncol., 82, 273-278.
2. Balmain A and Harris CC. (2000). Carcinogenesis, 21, 371-377.
3. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M and Jackson DG. (1999). J. Cell Biol., 144, 789-801.
4. Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, van Trappen P, Cox G, Harris AL and Jackson DG. (2002). Cancer Res., 62, 1315-1320.
5. Bergers G, Javaherian K, Lo KM, Folkman J and Hanahan D. (1999). Science, 284, 808-812.
6. Bleuel K, Popp S, Fusenig NE, Stanbridge EJ and Boukamp P. (1999). Proc. Natl. Acad. Sci. USA, 96, 2065-2070.
7. Bornstein P. (2001). J. Clin. Invest., 107, 929-934.
8. Brekken RA, Huang X, King SW and Thorpe PE. (1998). Cancer Res., 58, 1952-1959.
9. Castle V, Varani J, Fligiel S, Prochownik EV and Dixit V. (1991). J. Clin. Invest., 87, 1883-1888.
10. Detmar M, Brown LF, Schön MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP and Jain RK. (1998). J. Invest. Dermatol., 111, 1-6.
11. DiGiovanni J. (1992). Pharmacol. Ther., 54, 63-128.
12. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH and Augustin HG. (2000). Cancer Res., 60, 1388-1393.
13. Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clezardin P, Bouck N and Cabon F. (2001). Genes Dev., 15, 1373-1382.
14. Hawighorst T, Skobe M, Streit M, Hong YK, Velasco P, Brown LF, Riccardi L, Lange-Asschenfeldt D and Detmar M. (2002). Am. J. Pathol., 160, 1381-1392.
15. Hawighorst T, Velasco P, Streit M, Hong YK, Kyriakides TR, Brown LF, Bornstein P and Detmar M. (2001). EMBO J., 20, 2631-2640.
16. Holmgren L, O'Reilly MS and Folkman J. (1995). Nat. Med., 1, 149-153.
17. Ito N, Hasegawa R, Imaida K, Hirose M, Asamoto M and Shirai T. (1995). Crit. Rev. Oncol. Hematol., 21, 105-133.
18. Jackson DG, Prevo R, Clasper S and Banerji S. (2001). Trends Immunol., 22, 317-321.
19. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL and Bouck N. (2000). Nature Med., 6, 41-48.
20. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M and Alitalo K. (2001). Cancer Res., 61, 1786-1790.
21. Kodama J, Hashimoto I, Seki N, Hongo A, Yoshinouchi M, Okuda H and Kudo T. (2001). Clin. Cancer Res., 7, 2826-2831.
22. Lawler J. (2000). Curr. Opin. Cell Biol., 12, 634-640.
23. Leone A, Flatow U, VanHoutte K and Steeg PS. (1993). Oncogene, 8, 2325-2333.
24. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G and Pepper MS. (2001). EMBO J., 20, 672-862.
25. Marks F and Furstenberger G. (2000). Eur. J. Cancer., 36, 314-329.
26. Oliver G and Detmar M. (2002). Genes Dev., 16, 773-783.
27. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Bouscher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL and Jain RK. (2002). Science, 296, 1883-1886.
28. Prevo R, Banerji S, Ferguson DJ, Clasper S and Jackson DG. (2001). J. Biol. Chem., 276, 19420-19430.
29. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J and Iruela-Arispe ML. (2001). Proc. Natl. Acad. Sci. USA, 98, 12485-12490.
30. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K and Detmar M. (2001). Nat. Med., 7, 192-198.
31. Sleeman JP. (2000). Recent Results Cancer Res., 157, 55-81.
32. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H and Achen MG. (2001). Nat. Med., 7, 186-191.
33. Streit M, Velasco P, Brown LF, Skobe M, Richard L, Riccardi L, Lawler J and Detmar M. (1999). Am. J. Pathol, 155, 441-452.
34. Streit M, Velasco P, Riccardi L, Spencer L, Brown LF, Janes L, Lange-Asschenfeldt B, Yano K, Hawighorst T, Iruela-Arispe L and Detmar M. (2000). EMBO J., 19, 3272-3282.
35. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ and Bouck N. (1993). J. Cell Biol., 122, 497-511.
36. Tuszynski GP and Nicosia RF. (1996). Bioessays, 18, 71-76.
37. Volpert OV, Stellmach V and Bouck N. (1995). Breast Cancer Res. Treat., 36, 119-126
38. Weinstat SD, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD and Steeg PS. (1994). Cancer Res., 54, 6504-6511.
39. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, Jackson DG and Oliver G. (2002). EMBO J., 21, 1505-1513.
40. Wigle JT and Oliver G. (1999). Cell, 98, 769-778.
41. Yuspa S.H. (1994). Cancer Res., 54, 1178-1189.
42. Zabrenetzky V, Harris CC, Steeg PS and Roberts DD. (1994). Int. J. Cancer, 59, 191-195.